Cornea/External Disease News

BOSTON — Annual exams with topography are key to identifying progression in patients with keratoconus regardless of whether they have undergone cross-linking, according to a speaker here.

BOSTON — In this Healio Video Perspective from Eyecelerator@ASCRS, Greg Kunst, CEO of Aurion Biotech, discusses the company’s cell therapy for corneal endothelial disease.

NEW YORK — Topography-guided PRK and CTAK can change the corneal curvature in patients with keratoconus, according to a speaker at Vision Expo East.

The first Canadian patient has been dosed in a phase 1/2 trial of a cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction, according to a press release.

Nearly 5 months after the FDA did not approve reproxalap for dry eye, Aldeyra Therapeutics has announced a plan to resubmit a new drug application for the reactive aldehyde species modulator, according to a press release.

WAILEA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2024, Douglas Katsev, MD, and Julia Katsev Larson, OD, discuss the use of Miebo for dry eye disease.

Okyo Pharma has announced additional findings from its phase 2 trial of OK-101, including statistically significant improvement in ocular pain relief, conjunctival staining and tear breakup time in patients with dry eye disease.

Although we all learned about corneal disease in optometry school, both the understanding of keratoconus and expanding protocols for its treatment have changed dramatically since many practicing optometrists graduated.

When children and teens present with early onset of keratoconus, we often see severe disease and rapid progression.

NEW YORK — Reimbursement and pipeline products, as well as educating patients and doctors about Demodex blepharitis, remain priorities for Tarsus Pharmaceuticals in the wake of Xdemvy’s launch, a company executive said at Vision Expo East.